Medindia

X

Tianyin Pharmaceutical Co., Inc. Has Four Products Included in China's Essential Drug List

Thursday, September 17, 2009 General News J E 4
Advertisement
CHENGDU, China, Sept. 10 /PRNewswire-Asia-FirstCall/ - TianyinPharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier ofmodernized traditional Chinese medicine ("TCM") based in Chengdu, China, todayannounced that it has four products included in China's Essential Drug List(EDL) released by the Chinese government on August 18. The four genericproducts are Azithromycin Dispersible Tablets, Simvastatin Tablets, HuganTablets and Xiao Yan Li Dan Capsules and Tablets.

All the drugs in the Essential Drug List will be included in China's basichealth insurance catalog with a higher reimbursement percentage. Meanwhile,the pricing of the Essential Drugs will be decided by the governments throughpublic tender at the provincial level. The distribution of Essential Drugswill also be carried out through unified channels by either drug manufacturersor drug distributors. Companies winning the government tenders will have thepotential to significantly increase sales while margins on generic and morecommonly used drugs will see pricing control from the government.

As a result of this inclusion, management expects the sales of these fourdrugs could potentially increase from $6.1 million in fiscal year 2009 toapproximately $12 million in fiscal year 2010, which ends June 30, 2010.

"The release of China's essential drug list ensures that most ruralcitizens with comparatively low income will have access to cheap and safemedicines," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc.,commented. "We view this inclusion as an opportunity to significantlyincrease revenues generated from these products."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 39 products, 22 of which are listed in the highly selectiveNational Medicine Catalog of the National Medical Insurance program. Tianyinowns and operates two GMP manufacturing facilities and an R&D platformsupported by leading Chinese academic institutions. The Company has apipeline of 40 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Provincewith two manufacturing facilities and a total of 1,365 employees. Tianyinachieved revenue of approximately $33.5 million and net income ofapproximately $6 million in FY2008 ending June 30, 2008. For more informationabout Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO China Tel: +86-158-2122-5642 Email: Allen.y.tang@gmail.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: matt.hayden@hcinternational.net

SOURCE Tianyin Pharmaceutical Co., Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VitaPath Genetics Raises $6M in Series A Round
S
MDS Reports Third Quarter 2009 Financial Results